# US 2026/0102334 A1 · Dopa decarboxylase inhibitor compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0102334 A1
- Document ID: US20260102334A1
- Status: Published application
- Kind: A1
- Application number: 19/214,470
- Filed: 2025-05-21
- Published: 2026-04-16
- Earliest claimed: 2014-03-13
- Assignees: NeuroDerm, Ltd.
- Applicants: NeuroDerm, Ltd.
- Inventors: Oron Yacoby-Zeevi
- Web page: https://patentgrep.com/patent/US20260102334A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/133: having hydroxy groups, e.g. sphingosine
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 25/16: Anti-Parkinson drugs
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.

## Claims

### Claim 1

A pharmaceutically acceptable formulation comprising:
(i) levodopa, about 0.1% to about 6% by weight carbidopa, about 1% to about 25% by weight of a component selected from the group consisting of arginine, meglumine, and a combination thereof, and at least one o-quinone scavenger; or
(ii) about 8% to about 16% by weight levodopa, about 1% to about 4% by weight carbidopa, about 0.1% to about 40% by weight of a component selected from arginine, meglumine, and a combination thereof, and at least one o-quinone scavenger,
wherein the pharmaceutically acceptable formulation has less than about 1 μg/ml of hydrazine, as determined by a gas chromatography-mass spectrometry (GCMS) method.

### Claim 2 (depends on 1)

The formulation of claim 1 having less than about 0.1 μg/ml of hydrazine, as determined by a GCMS method.

### Claim 3 (depends on 1)

The formulation of claim 1 having about 0.1 to about 0.5 μg/ml of hydrazine.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein said o-quinone scavenger is selected from the group consisting of ascorbic acid or a salt thereof, L-cysteine, N-acetylcysteine (NAC), glutathione, diacetylcystine and/or a salt thereof, and a combination thereof.

### Claim 5 (depends on 1)

The formulation of claim 1, further comprising:
about 0.1% to about 10% by weight ascorbic acid or a salt thereof, and
a component selected from the group consisting of about 0.01% to about 1% by weight of NAC, about 0.01% to about 1% by weight L-cysteine, about 0.001% to about 1% by weight glutathione, and about 0.001% to about 1% by weight diacetylcystine or a salt thereof.

### Claim at position 6

-11. (canceled)

### Claim 12

A pharmaceutically acceptable formulation comprising:
(a) carbidopa;
(b) ascorbic acid or a salt thereof; and
(c) one of L-cysteine, NAC, glutathione, and diacetylcystine, or a salt thereof, wherein said formulation has less than about 1 μg/ml of hydrazine, as determined by a GCMS method.

### Claim 13 (depends on 12)

The formulation of claim 12 having less than about 0.1 μg/ml of hydrazine, as determined by a GCMS method.

### Claim 14

(canceled)

### Claim 15 (depends on 12)

The formulation of claim 12 comprising about 0.1% to 10% by weight ascorbic acid or salt thereof.

### Claim at position 11

-17. (canceled)

### Claim 18 (depends on 12)

The formulation of claim 12, comprising about 0.01% to about 1% by weight L-cysteine, or a salt thereof.

### Claim 19

(canceled)

### Claim 20 (depends on 12)

The formulation of claim 12 comprising about 0.1% to about 10% by weight carbidopa.

### Claim at position 15

-26. (canceled)

### Claim 27 (depends on 12)

The formulation of claim 12, further comprising levodopa.

### Claim at position 17

-31. (canceled)

### Claim 32 (depends on 12)

The formulation of claim 12 further comprising arginine, meglumine, or combination thereof.

### Claim at position 19

-34. (canceled)

### Claim 35 (depends on 1)

The formulation of claim 1, further comprising a surfactant.

### Claim at position 21

-50. (canceled)

### Claim 51 (depends on 1)

The formulation of claim 1, wherein the pharmaceutically acceptable formulation is a liquid formulation.

### Claim at position 23

-77. (canceled)

### Claim 78 (depends on 1)

A method for treating a disease or condition associated with loss of dopamine or dopaminergic neurons in a patient, said method comprising administering to the patient an amount of the pharmaceutically acceptable formulation of claim 1 in an amount effective to said disease or condition in the patient.

### Claim 79 (depends on 78)

The method of claim 78 wherein said disease is Parkinson's disease.

### Claim 80 (depends on 78)

The method of claim 78, wherein said administration is substantially continuous.

### Claim 81

(canceled)

### Claim 82

A method of reducing the impurities in a formulation containing levodopa and carbidopa, said method comprising:
(a) mixing together levodopa and/or carbidopa, and a component selected from L-arginine or meglumine, and antioxidants;
(b) add the mixture of step (a) into pre-heated water or bring the mixture at a temperature and for a time sufficient to dissolve the powders to form a solution;
(c) cooling the solution to room temperature.

### Claim 83 (depends on 82)

The method of claim 82, further comprising:
(d) adding additional water, antioxidants, and/or Tween-80, to the solution of step (c).

### Claim 84 (depends on 82)

The method of claim 82 wherein the water in step (b) comprises antioxidants prior to said mixing.

### Claim at position 31

-90. (canceled)
